{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"The proportion of participants with a reported change of grade \\>= 2 hearing impairments based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (for patients on a monitoring program with audiogram) will be reported.","groups":[{"description":"Participants undergo standard of care radiation therapy daily in combination with cisplatin on day 1. Between 4-5 hours after each cisplatin infusion, patients also receive sodium thiosulfate over 1-2 hours on day 1. Treatment will continue on either a 1 week or 3 week cycle per physician discretion for up to 6-7 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Cisplatin, Radiotherapy, STS"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 18 weeks","title":"Proportion of Participants With Reported High Grade Ototoxicity","type":"SECONDARY","unitOfMeasure":"proportion of participants"}